Jade Biosciences 3Q 2026: EPS ($0.42) — 10-Q Summary

Jade Biosciences reported a wider net loss of $35.06M in Q3 2026, with no revenue and higher operating expenses. Diluted EPS was ($0.42). The company has $475.7M in cash and expects it to last 12 months. Clinical trials for JADE101, JADE201, and JADE301 are ongoing, with data expected in 2027.

Original reporting
Published Nov 13, 2026, 12:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 12:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jade Biosciences 3Q 2026: EPS ($0.42) — 10-Q Summary — source image
Decision brief

The 30-second read

$JBIOBearishLow
01

Why it matters

The earnings miss may trigger short‑term price declines, but the cash position and upcoming trial data provide potential upside catalysts.

02

Market read

Primary earnings disclosure for a micro‑cap biotech; relevant for short‑term traders and longer‑term investors monitoring trial pipelines.

03

What to watch

Upcoming Phase 2 data for JADE101 and Phase 1 data for JADE201 could catalyze a rebound if results are positive.

Relevance 7/10Novelty 7/10Timing: post‑market release

Background

Jade Biosciences filed its Q3 2026 10‑Q, reporting widened losses, no revenue, and cash sufficient for 12 months.

Company-level read

Ticker impact

$JBIOBearishMedium confidence
Context

Q3 2026 net loss widened to $35.06M, EPS -$0.42, cash $475.7M, no revenue reported.

Expected impact

likely downward pressure as market prices in widened loss and lack of revenue

Evidence & confidence

The 10‑Q shows a larger net loss and no revenue, which typically triggers sell‑offs in biotech stocks.

Market effects

Biotech sector may see modest pullback as earnings miss highlights funding pressures.

US biotech investors may adjust exposure; limited broader market effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

The sizable cash runway ($475M) could support upcoming trials, offering a longer‑term upside despite the loss.

Key entities

  • Jade Biosciences, Inc.

    US‑listed biotech focused on renal and autoimmune therapies.

Related articles

$JBIOMed

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update • JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 • JADE101 Phase 2 clinical trial in IgA nephropathy (J

MedAI 8/10

BTIG reiterates Buy rating on Jade Biosciences, $77 price target

BTIG reiterated a Buy rating on Jade Biosciences with a $77 price target, implying a 431% upside from the Oct 26 close of $14.50. The target is based on strong clinical data for JADE101, showing a 70% reduction in IgA levels, and rapid clinical trial advancements, including a Phase 3 trial expected in 4Q26.